The Long Run with Luke Timmerman podcast

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

0:00
1:07:34
Retroceder 15 segundos
Avanzar 15 segundos
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Otros episodios de "The Long Run with Luke Timmerman"